Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb;204(2):606-611.
doi: 10.1111/bjh.19285. Epub 2024 Jan 8.

Acquired haemophilia A in paediatric patients: A retrospective French cohort of eight cases

Paul Mouthon  1 , Alexandre Guy  1   2 , Roseline d'Oiron  3   4 , Annie Harroche  5 , Aurélien Lebreton  6   7 , Clément Gourguechon  8 , Caroline Oudot-Challard  9 , Yoann Huguenin  1   10
Affiliations

Acquired haemophilia A in paediatric patients: A retrospective French cohort of eight cases

Paul Mouthon et al. Br J Haematol. 2024 Feb.

Abstract

Acquired haemophilia A (AHA) is a rare haemorrhagic disease characterised by new-onset haemorrhagic symptoms associated with a dramatic decrease in factor VIII levels and an anti-factor VIII neutralising autoantibody concentration >0.6 Bethesda units. Elderly people are often affected, whereas children are rarely affected; the paediatric incidence reported in the literature is about 0.045 case/million/year. For some time, the paediatric standard of care has been that for adults, but clinicians have often reported poor outcomes. Here, we describe the largest retrospective paediatric AHA cohort assembled to date, including eight patients diagnosed in France from 2000 to 2020.

Keywords: acquired factor VIII inhibitor; acquired haemophilia A; haemorrhage; paediatrics.

PubMed Disclaimer

References

REFERENCES

    1. Ling M, Duncan EM, Rodgers SE, Somogyi AA, Crabb GA, Street AM, et al. Classification of the kinetics of factor VIII inhibitors in haemophilia A: plasma dilution studies are more discriminatory than time-course studies: kinetics of FVIII inhibitors in haemophilia A. Br J Haematol. 2001;114(4):861-867.
    1. Knoebl P, Marco P, Baudo F, Collins P, Huth-Kühne A, Nemes L, et al. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2): demographics of acquired hemophilia A. J Thromb Haemost. 2012;10(4):622-631.
    1. Kruse-Jarres R, Kempton CL, Baudo F, Collins PW, Knoebl P, Leissinger CA, et al. Acquired hemophilia A: updated review of evidence and treatment guidance. Am J Hematol. 2017;92(7):695-705.
    1. Tiede A, Collins P, Knoebl P, Teitel J, Kessler C, Shima M, et al. International recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica. 2020;105(7):1791-1801.
    1. Borg JY, Guillet B, Le Cam-Duchez V, Goudemand J, Lévesque H; The SACHA Study Group. Outcome of acquired haemophilia in France: the prospective SACHA (Surveillance des Auto antiCorps au cours de l'Hémophilie Acquise) registry. Haemophilia. 2013;19(4):564-570.

Supplementary concepts

LinkOut - more resources